Back to top
more

Orthofix Medical (OFIX)

(Real Time Quote from BATS)

$12.60 USD

12.60
49,638

+0.29 (2.36%)

Updated Aug 6, 2025 10:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks News

Zacks Equity Research

Orthofix's (OFIX) New Launch to Benefit the MIS Spine Market

Orthofix (OFIX) announces the commercial launch and the successful completion of the first cases in the United States with the 7D FLASH Navigation System Percutaneous Module 2.0.

Zacks Equity Research

Orthofix (OFIX) Q2 Earnings and Revenues Surpass Estimates

Orthofix (OFIX) delivered earnings and revenue surprises of 102.99% and 1.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Orthofix (OFIX) Advances in ALIF Procedure With New Launch

Orthofix (OFIX) WaveForm A interbody features a wave-like design, providing a balance of strength, porosity and stability, along with a large implant graft aperture for bone graft material.

Zacks Equity Research

Orthofix (OFIX) Reports Q1 Loss, Tops Revenue Estimates

Orthofix (OFIX) delivered earnings and revenue surprises of 50% and 3.79%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Boston Scientific (BSX) Hits 52-Week High: What's Driving It?

Boston Scientific (BSX) outperforms the industry and the S&P 500 due to several new acquisitions and the long-term growth prospects of the WATCHMAN device.

Zacks Equity Research

Here's Why You Should Retain Amedisys (AMED) Stock for Now

Amedisys's (AMED) share price is likely to grow following an impressive fourth-quarter 2022 performance and new partnerships.

Zacks Equity Research

Why You Should Add Hologic (HOLX) to Your Portfolio Now

Hologic (HOLX) is currently well-positioned to achieve its full-year guidance of low double-digit organic growth ex-COVID in all three franchises, well above the 5-7% long-term growth rate.

Zacks Equity Research

Bruker Corporation (BRKR) Hits 52-Week High: What's Driving It?

Bruker Corporation (BRKR) outperforms the industry and the S&P 500 due to impressive quarterly results and segmental prospects.

Zacks Equity Research

Orthofix (OFIX) Q4 Earnings Beat Estimates, Gross Margin Dips

Orthofix (OFIX) reports impressive performance across the BGT and Global Orthopedics segment in the fourth quarter.

Zacks Equity Research

Orthofix (OFIX) Progresses With Limb-Lengthening Device

Orthofix's (OFIX) Fitbone TAA intramedullary limb-lengthening system is implanted through a minimally invasive procedure.

Zacks Equity Research

Here's Why You Should Retain Boston Scientific (BSX) Now

Investors are optimistic about Boston Scientific (BSX) on recent acquisitions and robust performance of the WATCHMAN device.

Zacks Equity Research

Amedisys (AMED) Faces Macro Challenges, Margin Pressure

The Contessa Health acquisition seems to be strategically aligned with Amedisys' (AMED) business.

Zacks Equity Research

Teleflex (TFX) OEM Arm Grows, Supply Issue Persists

From a geographic perspective, Teleflex (TFX) is seeing strong results in Asia, which continues to be an important growth driver for Teleflex.

Zacks Equity Research

Here's Why Investors Should Retain Zimmer Biomet (ZBH) Now

Investors are optimistic about Zimmer Biomet (ZBH) owing to ongoing business recovery from the COVID-led pandemic impact.

Zacks Equity Research

Globus Medical (GMED) Global Growth Strong Despite Margin Woe

Despite continued margin declines in Japan, Globus Medical (GMED) remains positive on the progress and potential of its international business for long-term growth as it continues to reset the market in the country.

Zacks Equity Research

Syneos Health (SYNH) Hurt by Low Reimbursable Expense, FX Issue

Syneos Health (SYNH) experiences delays in large pharma award decisions, with net awards being impacted by greater-than-normal delays.

Zacks Equity Research

Neogen (NEOG) Rises 7.9% Since Q1 Earnings: What's Driving It?

Investors are optimistic about Neogen's (NEOG) recent product launches and strong global presence.

Zacks Equity Research

Neogen (NEOG) Benefits From Advanced Portfolio, Global Growth

Barring Australia and China, solid international operations also buoy optimism for Neogen (NEOG).

Zacks Equity Research

Here's Why You Should Retain Hologic (HOLX) Stock for Now

Investors are optimistic about Hologic (HOLX), led by the continued strength of the GYN Surgical business.

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock Now

Investors are optimistic about Charles River (CRL) on robust performances across the RMS and DSA segments.

Zacks Equity Research

Insulet's (PODD) Omnipod Sales Aid, Costs Continue to Rise

Insulet (PODD) progresses well with respect to its four-pillar strategy, wherein the first two pillars include expanding access and awareness, and delivering consumer-focused innovation.

Zacks Equity Research

Abbott (ABT) to Upgrade PHCs Across India With New Pact

Abbott's (ABT) HWC program is likely to benefit more than 2.5 million people from under-resourced communities annually.

Zacks Equity Research

Omnicell (OMCL) Ailed by Mounting Costs, Macroeconomic Issues

Macroeconomic factors adversely affect bookings and revenues in Omnicell's (OMCL) point-of-care business. The company reduces its overall bookings and revenue outlook for the year.

Zacks Equity Research

SmileDirectClub (SDC) Gains From Innovation Amid Macro Issues

A series of cutting-edge innovations, strategic distribution and insurance partnerships are added positives for SmileDirectClub (SDC).